[4-(Pyrimidin-2-ylamino)cyclohexyl]carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: [4-(Pyrimidin-2-ylamino)cyclohexyl]carbamic acid
• 英文别名: [4-(pyrimidin-2-ylamino)cyclohexyl]carbamic acid
• 化学式: C₁₁H₁₆N₄O₂
• 分子量: 236.27
• InChiKey: GEPQUDRRZRTISP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  87.1
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DE CD73 ET LEURS INDICATIONS
  申请人：PLEXXIKON INC

  公开号：WO2021113625A1

  公开（公告）日：2021-06-10

  Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

  揭示了Formula I的化合物：或其药用可接受盐、溶剂化合物、互变异构体、立体异构体或氘代谢物，其中R1、R2、R3、A、L和G如本公开说明书中的任何实施例中所描述；以及这些化合物的组合物和用途。
• DNA-PK inhibitors
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10258627B2

  公开（公告）日：2019-04-16

  The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及可用作 DNA-PK 抑制剂的化合物。本发明还提供了包含所述化合物的药学上可接受的组合物，以及使用该组合物治疗各种疾病、病症或失调的方法。
• Substituted quinoxaline DNA-PK inhibitors
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10973830B2

  公开（公告）日：2021-04-13

  The present invention relates to Provided are compounds of Formula (I): wherein R1, R2, X, Ring A, Ring B, and Ring C are as defined herein. Compounds of Formula (I) are useful as inhibitors of DNA-PK. Also provided are pharmaceutical compositions comprising said compounds and methods of using the compounds and compositions in the treatment of various diseases, conditions, and disorders.

  本发明涉及 提供式（I）化合物： 其中 R1、R2、X、环 A、环 B 和环 C 如本文所定义。式（I）化合物可用作 DNA-PK 的抑制剂。此外，还提供了包含上述化合物的药物组合物，以及使用这些化合物和组合物治疗各种疾病、病症和失调的方法。
• 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US11053234B2

  公开（公告）日：2021-07-06

  A compound of formula (I) wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式 (I) 的化合物 其中 R、R1、R2、R3、Y、Y1、a、X 和 Z 如本文所定义。 本发明的化合物是造血前列腺素 D 合酶（H-PGDS）的抑制剂，可用于治疗杜氏肌肉萎缩症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物抑制 H-PGDS 活性和治疗相关疾病的方法。
• DNA-PK INHIBITORS
  申请人：Vertex Pharmaceuticals Inc.

  公开号：EP2970218B1

  公开（公告）日：2018-11-28